Randomized, Controlled, Multicenter Phase III Trial of Standard-Dose Fluorouracil-Epirubicin- Cyclophosphamide (FEC), Compared with Time-Intensive FEC (FEC-G) and Mitoxantrone-Methotrexate-Mitomycin C (MMM-G) in Metastatic Breast Carcinoma

A.M. Capotorto; L. Pavesi; P. Pedrazzoli; G.A. Da Prada; C. Zamagni; B. Massidda; A. Farris; A. Martoni; G. Lelli; G. Robustelli Della Cuna

doi:10.1179/joc.2003.15.2.184

Randomized, Controlled, Multicenter Phase III Trial of Standard-Dose Fluorouracil-Epirubicin- Cyclophosphamide (FEC), Compared with Time-Intensive FEC (FEC-G) and Mitoxantrone-Methotrexate-Mitomycin C (MMM-G) in Metastatic Breast Carcinoma

Journal of Chemotherapy ◽

10.1179/joc.2003.15.2.184 ◽

2003 ◽

Vol 15 (2) ◽

pp. 184-191 ◽

Cited By ~ 12

Author(s):

A.M. Capotorto ◽

L. Pavesi ◽

P. Pedrazzoli ◽

G.A. Da Prada ◽

C. Zamagni ◽

...

Keyword(s):

Breast Carcinoma ◽

Mitomycin C ◽

Standard Dose ◽

Metastatic Breast ◽

Phase Iii ◽

Phase Iii Trial ◽

Metastatic Breast Carcinoma ◽

Randomized Controlled ◽

Multicenter Phase

Download Full-text

Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)

Trials ◽

10.1186/s13063-020-04341-y ◽

2020 ◽

Vol 21 (1) ◽

Cited By ~ 1

Author(s):

Toshinari Yamashita ◽

Norikazu Masuda ◽

Shigehira Saji ◽

Kazuhiro Araki ◽

Yoshinori Ito ◽

...

Keyword(s):

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Eribulin Mesylate ◽

Phase Iii Trial ◽

Randomized Controlled ◽

Breast Cancer Study

Download Full-text

Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor‐Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care‐BC): A Randomized Controlled Phase III Trial

The Oncologist ◽

10.1634/theoncologist.2019-0382 ◽

2019 ◽

Vol 25 (2) ◽

Cited By ~ 2

Author(s):

Naoki Niikura ◽

Katsuhiko Nakatukasa ◽

Takeshi Amemiya ◽

Ken‐ichi Watanabe ◽

Hironobu Hata ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Oral Care ◽

Metastatic Breast ◽

Phase Iii ◽

Breast Cancer Patients ◽

Phase Iii Trial ◽

Randomized Controlled ◽

Estrogen Receptor Positive ◽

Care Evaluation

Download Full-text

Abstract P1-11-01: Oral care evaluation to prevent oral mucositis in estrogen receptor positive metastatic breast cancer patients treated with everolimus (Oral Care-BC): A randomized controlled phase III trial

10.1158/1538-7445.sabcs18-p1-11-01 ◽

2019 ◽

Cited By ~ 1

Author(s):

N Niikura ◽

K Nakatukasa ◽

T Amamiya ◽

K-i Watanabe ◽

H Hata ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Oral Care ◽

Metastatic Breast ◽

Phase Iii ◽

Breast Cancer Patients ◽

Phase Iii Trial ◽

Randomized Controlled ◽

Estrogen Receptor Positive ◽

Care Evaluation

Download Full-text

Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy

Cancer ◽

10.1002/(sici)1097-0142(19990101)85:1<104::aid-cncr15>3.0.co;2-r ◽

1999 ◽

Vol 85 (1) ◽

pp. 104-111 ◽

Cited By ~ 92

Author(s):

Zia U. Rahman ◽

Debbie K. Frye ◽

Terry L. Smith ◽

Lina Asmar ◽

Richard L. Theriault ◽

...

Keyword(s):

Breast Carcinoma ◽

Standard Dose ◽

Metastatic Breast ◽

Metastatic Breast Carcinoma ◽

Long Term Follow Up

Download Full-text

ESOPEC: A prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy to neoadjuvant chemoradiation in patients with adenocarcinoma of the esophagus (NCT02509286).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps4131 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS4131-TPS4131

Author(s):

Jens Hoeppner ◽

Florian Lordick ◽

Thomas B. Brunner ◽

Torben Glatz ◽

Claudia Schmoor ◽

...

Keyword(s):

Neoadjuvant Chemoradiation ◽

Phase Iii ◽

Perioperative Chemotherapy ◽

Adenocarcinoma Of The Esophagus ◽

Phase Iii Trial ◽

Randomized Controlled ◽

Multicenter Phase

Download Full-text

ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286)

BMC Cancer ◽

10.1186/s12885-016-2564-y ◽

2016 ◽

Vol 16 (1) ◽

Cited By ~ 77

Author(s):

Jens Hoeppner ◽

Florian Lordick ◽

Thomas Brunner ◽

Torben Glatz ◽

Peter Bronsert ◽

...

Keyword(s):

Neoadjuvant Chemoradiation ◽

Phase Iii ◽

Perioperative Chemotherapy ◽

Adenocarcinoma Of The Esophagus ◽

Phase Iii Trial ◽

Randomized Controlled ◽

Multicenter Phase

Download Full-text

Gemcitabine, epirubicin and paclitaxel (GET) vs. 5-fluorouracil, epirubicin and cyclophosphamide (FEC) as first-line treatment in metastatic breast cancer: interim toxicity analysis of a randomised, multicenter phase iii trial of the Central European Cooperative Oncology Group (CECOG)

European Journal of Cancer ◽

10.1016/s0959-8049(01)81201-6 ◽

2001 ◽

Vol 37 ◽

pp. S194

Author(s):

T. Brodowicz ◽

S. Beslija ◽

J. Cervek ◽

Z. Mrsic-Krmpotic ◽

I. Tchernozemsky ◽

...

Keyword(s):

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

Oncology Group ◽

First Line ◽

Phase Iii Trial ◽

Central European ◽

Multicenter Phase ◽

Toxicity Analysis ◽

First Line Treatment

Download Full-text

Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases

Annals of Surgical Oncology ◽

10.1245/s10434-015-4968-3 ◽

2015 ◽

Vol 23 (4) ◽

pp. 1309-1319 ◽

Cited By ~ 61

Author(s):

Marybeth S. Hughes ◽

Jonathan Zager ◽

Mark Faries ◽

H. Richard Alexander ◽

Richard E. Royal ◽

...

Keyword(s):

Liver Metastases ◽

Phase Iii ◽

Phase Iii Trial ◽

Hepatic Perfusion ◽

Randomized Controlled ◽

Multicenter Phase ◽

Percutaneous Hepatic Perfusion

Download Full-text

Evaluation of oral care to prevent oral mucositis in estrogen receptor-positive metastatic breast cancer patients treated with everolimus (Oral Care-BC): randomized controlled phase III trial

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyw077 ◽

2016 ◽

Vol 46 (9) ◽

pp. 879-882 ◽

Cited By ~ 5

Author(s):

Naoki Niikura ◽

Yoshihide Ota ◽

Naoki Hayashi ◽

Mariko Naito ◽

Kosuke Kashiwabara ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast Cancer ◽

Oral Care ◽

Metastatic Breast ◽

Phase Iii ◽

Breast Cancer Patients ◽

Phase Iii Trial ◽

Randomized Controlled ◽

Estrogen Receptor Positive

Download Full-text

Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial

Journal of Neuro-Oncology ◽

10.1007/s11060-010-0427-y ◽

2010 ◽

Vol 103 (3) ◽

pp. 595-602 ◽

Cited By ~ 21

Author(s):

Il Han Kim ◽

Chul-Kee Park ◽

Dae Seog Heo ◽

Chae-Yong Kim ◽

Chang Hun Rhee ◽

...

Keyword(s):

Phase Iii ◽

Newly Diagnosed ◽

Phase Iii Trial ◽

Randomized Controlled ◽

Multicenter Phase ◽

Adjuvant Temozolomide

Download Full-text